Adjunctive glucocorticoid therapy in patients with septic shock.
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses [354, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The three trials [354, 478, 479] also used different inclusion criteria: in ADRENAL [479] eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 h to maintain a MAP > 60 mmHg, and present at the time of randomisation.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationA Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.
Rhee, C., Dantes, R., Epstein, L., Murphy, D. J., Seymour, C. W., Iwashyna, T. J., Kadri, S. S., Angus, D. C., Danner, R. L., Fiore, A. E., et al. (2017) · JAMA · doi:10.1001/jama.2017.13836 · Cited by 1,884
Cited by
Items 101–200 of 1,000
Menon, V. P., Mohamed, Z. U., Prasannan, P., Moni, M., Edathadathil, F., Prasanna, P., Menon, A., Balachandran, S., Greeshma, C., Sathyapalan, D. T., et al. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23517 · Cited by 113
Bosch, N. A., Teja, B. J., Law, A. C., Pang, B., Jafarzadeh, S. R., & Walkey, A. J. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0258 · Cited by 91
Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis
Vandewalle, J., Timmermans, S., Paakinaho, V., Vancraeynest, L., Dewyse, L., Vanderhaeghen, T., Wallaeys, C., Wyngene, L. V., Looveren, K. V., Nuyttens, L., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.002 · Cited by 84
Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock
Pirracchio, R., Annane, D., Waschka, A. K., Lamontagne, F., Arabi, Y. M., Bollaert, P., Billot, L., Du, B., Briegel, J., Cohen, J., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300034 · Cited by 85
Self-citationMeduri, G. U., & Chrousos, G. P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00161 · Cited by 84
“The inclusion or exclusion of fludrocortisone, as a cointervention with hydrocortisone, may partly explain the differences reported in outcomes of some RCTs (see explanation for Figure 7 below) (292, 298).”
ResultRefractory septic shock: our pragmatic approach
Nandhabalan, P., Ioannou, N., Meadows, C. I. S., & Wyncoll, D. L. A. (2018) · Critical Care · doi:10.1186/s13054-018-2144-4 · Cited by 82
Glucocorticoids and the Brain after Critical Illness
Hill, A. R., & Spencer-Segal, J. L. (2021) · Endocrinology · doi:10.1210/endocr/bqaa242 · Cited by 90
Peeters, B., Meersseman, P., Vander Perre, S., Wouters, P. J., Vanmarcke, D., Debaveye, Y., Billen, J., Vermeersch, P., Langouche, L., & Van den Berghe, G. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5366-7 · Cited by 74
Community-acquired pneumonia as an emergency condition
Cillóniz, C., Dominedò, C., García‐Vidal, C., & Torres, A. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000550 · Cited by 76
Sanchez-Pinto, L. N., Stroup, E. K., Pendergrast, T. R., Pinto, N. P., & Luo, Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.9271 · Cited by 78
Huynh, D. T. N., Baek, N., Sim, S., Myung, C., & Heo, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186656 · Cited by 74
“Moreover, sepsis often affects the kidneys, resulting in sepsis-associated acute kidney injury that increases the risk of in-hospital death [4].”
BackgroundA review of gut failure as a cause and consequence of critical illness
Soranno, D. E., Coopersmith, C. M., Brinkworth, J. F., Factora, F. N., Muntean, J. H., Mythen, M. G., Raphael, J., Shaw, A., Vachharajani, V., & Messer, J. S. (2025) · Critical Care · doi:10.1186/s13054-025-05309-7 · Cited by 82
Hager, D. N., Hooper, M. H., Bernard, G. R., Busse, L. W., Ely, E. W., Fowler, A. A., Gaieski, D. F., Hall, A. J., Hinson, J. S., Jackson, J. C., et al. (2019) · Trials · doi:10.1186/s13063-019-3254-2 · Cited by 77
Stifel, U., Wolfschmitt, E.-M., Vogt, J. A., Wachter, U. A., Vettorazzi, S., Tews, D., Hogg, M., Zink, F., Koll, N., Winning, S., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101424 · Cited by 81
Lymphopenia in sepsis—an acquired immunodeficiency?
Finfer, S. R., Venkatesh, B., Hotchkiss, R. S., & Sasson, S. C. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12611 · Cited by 77
“Interestingly, there was some concordance in secondary endpoints, with both APPROCCHS and ADRENAL trials finding that treatment with corticosteroids was associated with reduced time to weaning vasopressors and mechanical ventilation.(4,7) One element likely hindering the field is the current “one-size-fits-all” approa…”
ResultSelf-citationLow-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review
Pirracchio, R., Venkatesh, B., & Legrand, M. M. (2024) · JAMA · doi:10.1001/jama.2024.6096 · Cited by 76
Self-citationTiming of vasoactive agents and corticosteroid initiation in septic shock
Ammar, M. A., Ammar, A. A., Wieruszewski, P. M., Bissell, B. D., Long, M. T., Albert, L., Khanna, A. K., & Sacha, G. L. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01021-9 · Cited by 78
“In contrast, the Corticosteroid Therapy of Septic Shock (CORTICUS) trial and the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial failed to demonstrate survival benefit [65, 66].”
ResultThe initial resuscitation of septic shock
Cinel, I., Kasapoglu, U. S., Gul, F., & Dellinger, R. P. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.02.004 · Cited by 69
den Berghe, G. V., Téblick, A., Langouche, L., & Gunst, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104284 · Cited by 76
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
The REMAP-CAP Investigators, Heming, N., Berry, L., Lorenzi, E., Hills, T. E., Higgins, A. M., Arabi, Y., Aryal, D., Beane, A., Best-Lane, J., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07861-w · Cited by 71
Self-citationLtaief, Z., Ben‐Hamouda, N., Rancati, V., Gunga, Z., Marcucci, C., Kirsch, M. E. W., & Liaudet, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216407 · Cited by 86
Blood Purification Techniques for Sepsis and Septic AKI
Girardot, T., Schneider, A. G., & Rimmele, T. R. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.06.010 · Cited by 65
The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3
Ding, R., Meng, Y., & Ma, X. (2018) · BioMed Research International · doi:10.1155/2018/5086516 · Cited by 71
“However, in ADRENAL Trial, hydrocortisone (200 mg/day for 7 days) did not improve the prognosis of patients with septic shock undergoing mechanical ventilation [63].”
BackgroundApoptotic cell therapy for cytokine storm associated with acute severe sepsis
Karbian, N., Abutbul, A., el-Amore, R., Eliaz, R., Beeri, R., Reicher, B., & Mevorach, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02748-8 · Cited by 65
Disease Mechanisms of Perioperative Organ Injury
Conrad, C., & Eltzschig, H. K. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005191 · Cited by 72
Critical Illness–induced Corticosteroid Insufficiency: What It Is Not and What It Could Be
Téblick, A., Gunst, J., & den Berghe, G. V. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac201 · Cited by 71
Estimating Sepsis Incidence Using Administrative Data and Clinical Medical Record Review
Mellhammar, L., Wollter, E., Dahlberg, J., Donovan, B., Olseén, C.-J. V., Wiking, P. O., Rose, N., Schwarzkopf, D., Friedrich, M. E., Fleischmann-Struzek, C., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.31168 · Cited by 70
Sartelli, M., Tascini, C., Coccolini, F., Dellai, F., Ansaloni, L., Antonelli, M. M., Bartoletti, M., Bassetti, M., Boncagni, F., Carlini, M., et al. (2024) · World Journal of Emergency Surgery · doi:10.1186/s13017-024-00551-w · Cited by 77
“Although these studies failed to show a reduction in 28-day mortality, corticosteroids provided significantly faster resolution of shock and more rapid weaning from mechanical ventilation without increasing the infection rate [63, 64].”
BackgroundManagement of Sepsis in Patients With Cirrhosis: Current Evidence and Practical Approach
Simonetto, D. A., Serafim, L. P., de Moraes, A. G., Gajic, O., & Kamath, P. S. (2018) · Hepatology · doi:10.1002/hep.30412 · Cited by 64
“A recent large, multicenter trial showed that hydrocortisone alone does not reduce mortality compared to placebo,(61) whereas another recent study demonstrated that combination hydrocortisone plus fludrocortisone may improve 90-day survival in patients with septic shock.”
BackgroundEvaluating Vitamin C in Septic Shock: A Randomized Controlled Trial of Vitamin C Monotherapy*
Wacker, D. A., Burton, S. L., Berger, J. P., Hegg, A. J., Heisdorffer, J., Wang, Q., Medcraft, E. J., & Reilkoff, R. A. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005427 · Cited by 63
Heming, N., Renault, A., Kuperminc, E., Brun‐Buisson, C., Mégarbane, B., Quenot, J., Siami, S., Cariou, A., Forceville, X., Schwebel, C., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00430-7 · Cited by 62
Perioperative Immunosuppressive Factors during Cancer Surgery: An Updated Review
Bezu, L., Öksüz, D. A., Bell, M., Buggy, D. J., Díaz‐Cambronero, Ó., Enlund, M., Forget, P., Gupta, A. K., Hollmann, M. W., Ionescu, D. C., et al. (2024) · Cancers · doi:10.3390/cancers16132304 · Cited by 77
“In patients with a dysfunctional HPA, perioperative cortisone supplementation may improve postoperative outcomes [77].”
BackgroundFielding‐Singh, V., Matthay, M. A., & Calfee, C. S. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003406 · Cited by 61
Imbalance of Circulating Innate Lymphoid Cell Subpopulations in Patients With Septic Shock
Carvelli, J., Pipéroglou, C., Bourenne, J., Farnarier, C., Banzet, N., Demerle, C., Gainnier, M., & Vely, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02179 · Cited by 58
Panwar, R., Tarvade, S., Lanyon, N., Saxena, M. K., Bush, D., Hardie, M. J., Attia, J., Bellomo, R., & van Haren, F. M. P. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201912-2316oc · Cited by 58
Self-citationAntimicrobial Treatment Duration in Sepsis and Serious Infections
Busch, L. M., & Kadri, S. S. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa247 · Cited by 63
Population enrichment for critical care trials: phenotypes and differential outcomes
Shankar‐Hari, M., & Rubenfeld, G. D. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000641 · Cited by 61
“This is illustrated in two recent corticosteroid trials in septic shock, where the trial with higher mortality showed better risk reduction [52,53].”
ResultBosch, N. A., Cohen, D. M., & Walkey, A. J. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003560 · Cited by 57
Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?
Kamath, S., Altaq, H. H., & Abdo, T. (2023) · Microorganisms · doi:10.3390/microorganisms11092231 · Cited by 69
“Although patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation, there was no significant difference in the number of days alive and free of mechanical ventilation [171].”
Anterior pituitary function in critical illness
Téblick, A., Langouche, L., & Van den Berghe, G. (2019) · Endocrine Connections · doi:10.1530/ec-19-0318 · Cited by 52
Jiang, C., Zhang, J., Xie, H., Guan, H., Li, R., Chen, C., Dong, H., Zhou, Y., & Zhang, W. K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112408 · Cited by 56
Ma, Y., Liu, Y., Hou, H., Yao, Y., & Meng, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.168 · Cited by 52
Rationale of Hemoadsorption during Extracorporeal Membrane Oxygenation Support
Napp, L. C., Ziegeler, S., & Kindgen‐Milles, D. (2019) · Blood Purification · doi:10.1159/000500015 · Cited by 56
Barnes, T. J., Hockstein, M. A., & Jabaley, C. S. (2020) · SAGE Open Medicine · doi:10.1177/2050312120935466 · Cited by 54
Paik, S., Choe, J. H., Choi, G.-E., Kim, J.-E., Kim, J., Song, G., & Jo, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40690-8 · Cited by 52
Corticosteroids for Treating Sepsis in Adult Patients: A Systematic Review and Meta-Analysis
Liang, H., Song, H., Zhai, R., Song, G., Li, H., Ding, X., Kan, Q., & Sun, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709155 · Cited by 62
“(64) RCT M 03/2013 −04/2017 3,658/1,832 CS: 62.”
Sato, R., Hasegawa, D., Prasitlumkum, N., Ueoka, M., Nishida, K., Takahashi, K., Nasu, M., & Dugar, S. P. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005263 · Cited by 50
The role of thromboinflammation in acute kidney injury among patients with septic coagulopathy
Iba, T., Helms, J., Maier, C. L., Levi, M. M., Scărlătescu, E., & Levy, J. H. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.02.006 · Cited by 56
Tsai, M., Yang, K., Chan, M.-C., Kao, K., Wang, H., Perng, W., Wu, C., Liang, S., Fang, W., Tsai, J., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-0642-4 · Cited by 53
Hammond, N. E., Finfer, S. R., Li, Q., Taylor, C. B., Cohen, J., Arabi, Y. M., Bellomo, R., Billot, L., Harward, M. L., Joyce, C., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06169-1 · Cited by 55
“[11] The follow-up was conducted by trained research coordinators who were blinded to the treatment allocation.”
InfluentialSelf-citationDeciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Soulountsi, V., Schizodimos, T., & Kotoulas, S. (2021) · Infection · doi:10.1007/s15010-021-01640-7 · Cited by 59
Lesur, O., Delile, E., Asfar, P., & Radermacher, P. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0449-8 · Cited by 56
Gálvez-Romero, J. L., Palmeros-Rojas, O., Real‐Ramírez, F. A., Sánchez-Romero, S., Tome‐Maxil, R., Ramírez-Sandoval, M. D. L. P., Olivos‐Rodríguez, R., Flores‐Encarnación, S. E., Cabrera‐Estrada, A. A., Ávila‐Morales, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13223 · Cited by 50
Teja, B., Berube, M., Pereira, T. V., Law, A. C., Schanock, C., Pang, B., Wunsch, H., Walkey, A. J., & Bosch, N. A. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1785oc · Cited by 48
The role of glucocorticoids as adjunctive treatment for sepsis in the modern era
Marik, P. E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30265-0 · Cited by 50
Ascorbic Acid, Thiamine, and Steroids in Septic Shock: Propensity Matched Analysis
Sadaka, F. G., Grady, J., Organti, N. K., Donepudi, B., Korobey, M. J., Tannehill, D., & O’Brien, J. (2019) · Journal of Intensive Care Medicine · doi:10.1177/0885066619864541 · Cited by 49
Is Mortality a Useful Primary End Point for Critical Care Trials?
Veldhoen, R. A., Howes, D. W., & Maslove, D. M. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.11.019 · Cited by 50
Etomidate, Adrenal Insufficiency and Mortality Associated With Severity of Illness: A Meta-Analysis
Albert, S. G., & Sitaula, S. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066620957596 · Cited by 51
“Also, clarification of the effect of etomidate may not be forthcoming, as more recent prospective trials of corticosteroids in septic shock have specifically excluded patients receiving etomidate.(30,31) Although there Figure 3.”
BackgroundHealth Care–Associated Infections after Subarachnoid Hemorrhage
Abulhasan, Y. B., Alabdulraheem, N. S., Schiller, I., Rachel, S. P., Dendukuri, N., Angle, M. R., & Frenette, C. H. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.04.061 · Cited by 47
Jung, S., Lee, M., Baek, M. S., & Kim, W. (2022) · Critical Care · doi:10.1186/s13054-021-03872-3 · Cited by 48
“Low-dose corticosteroids have been shown to reverse septic shock [11, 12], although the use of hydrocortisone was not controlled in most of these trials [7, 9, 10].”
BackgroundHussain, H., Vutipongsatorn, K., Jiménez, B., & Antcliffe, D. B. (2022) · Metabolites · doi:10.3390/metabo12050376 · Cited by 51
Chow, J. H., Abuelkasem, E., Sankova, S. K., Henderson, R. A., Mazzeffi, M. A., & Tanaka, K. A. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004343 · Cited by 48
Early Recognition and Emergency Treatment of Sepsis and Septic Shock in Children
Hilarius, K. W. E., Skippen, P. W., & Kissoon, N. “. (2020) · Pediatric Emergency Care · doi:10.1097/pec.0000000000002043 · Cited by 49
Management of liver failure in general intensive care unit
Paugam‐Burtz, C., Levesque, É., Louvet, A., Thabut, D., Amathieu, R., Bureau, C., Camus, C., Chanques, G., Faure, S., Ferrandière, M., et al. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.06.014 · Cited by 54
Pediatric sepsis biomarkers for prognostic and predictive enrichment
Wong, H. R. (2021) · Pediatric Research · doi:10.1038/s41390-021-01620-5 · Cited by 47
Machine-learning-derived sepsis bundle of care
Kalimouttou, A., Lerner, I., Cheurfa, C., Jannot, A., & Pirracchio, R. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06928-2 · Cited by 50
“Steroid supplementation and glycemic control are both considered to be based on moderate quality of evidence [27–32].”
BackgroundThe Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 52
A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy
Ortoleva, J. P., & Cobey, F. C. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.11.025 · Cited by 44
Santhakumaran, S., Gordon, A. C., Prevost, A. T., O’Kane, C. M., McAuley, D. F., & Shankar‐Hari, M. (2019) · Critical Care · doi:10.1186/s13054-019-2446-1 · Cited by 44
Rapoport, B. L., Cooksley, T., Johnson, D. B., Anderson, R., & Shannon, V. R. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1884067 · Cited by 47
“controversial with contradictory results from large randomized controlled trials [50,51].”
ResultPotter, E., Hodgson, L. E., Creagh-Brown, B. C., & Forni, L. G. (2018) · Shock · doi:10.1097/shk.0000000000001239 · Cited by 51
“However, there was no difference in mortality, recurrence of shock, recurrence of mechanical ventilation, or requirement for renal replacement therapy (35).”
BackgroundTonnus, W., Gembardt, F., Latk, M., Parmentier, S. P., Hugo, C., Bornstein, S. R., & Linkermann, A. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0193-5 · Cited by 45
Smith, S., Liu, Y., Carter, A., Kennedy, B. J., Dermedgoglou, A., Poulgrain, S. S., Paavola, M. P., Minto, T. L., Luc, M., & Hanson, J. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007929 · Cited by 47
“The fact that corticosteroids were administered in patients with higher APACHE III scores possibly reflects the influence of the sepsis literature that has supported the use of corticosteroids to hasten the resolution of shock [44], or perhaps–more likely–it is an indication of clinicians’ limited therapeutic armament…”
BackgroundAssimakopoulos, S. F., Papadopoulou, I., Bantouna, D., de Lastic, A.-L., Rodi, M., Mouzaki, A., Gogos, C. A., Zolota, V., & Maroulis, I. (2021) · Shock · doi:10.1097/shk.0000000000001566 · Cited by 41
“Two large-scale randomized controlled trials on hydrocortisone in patients with septic shock (Adjunctive Glucocorticoid Therapy in Patients with Septic Shock and Activated Protein C and Corticosteroids for Human Septic Shock), demonstrated beneficial effects on morbidity with an excellent safety profile, with the Acti…”
BackgroundDexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
Zhang, Y., Hu, S., Wang, J., Xue, Z., Wang, C., & Wang, N. (2020) · Virology · doi:10.1016/j.virol.2020.12.001 · Cited by 43
“…possessing anti-inflammatory (Ayroldi et al., 2012; Coutinho and Chapman, 2011), anti-toxic, anti-allergic (McKeever et al., 2018), anti-shock (Venkatesh et al., 2018), non-specific immunosuppression and antifebrile effects, which can prevent the occurrence of immunological inflammatory…”
BackgroundAdrenergic Downregulation in Critical Care: Molecular Mechanisms and Therapeutic Evidence
Belletti, A., Landoni, G., Ломиворотов, В. В., Oriani, A., & Ajello, S. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.10.017 · Cited by 44
Severe Community-Acquired Pneumonia
Cillóniz, C., Dominedò, C., Liapikou, A., & Torres, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11487-4 · Cited by 41
Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression
Garduno, A., Cusack, R., Leone, M., Einav, S., & Martin-Loeches, I. (2023) · Microorganisms · doi:10.3390/microorganisms11051119 · Cited by 39
“Glucocorticoids appear to have beneficial effects in some patients and cause harm in others [135,136].”
BackgroundLangouche, L., Téblick, A., Gunst, J., & den Berghe, G. V. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad021 · Cited by 47
The glucocorticoid receptor and cortisol levels in pediatric septic shock
Alder, M. N., Opoka, A. M., & Wong, H. R. (2018) · Critical Care · doi:10.1186/s13054-018-2177-8 · Cited by 40
Use of IFNγ/IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock
König, R., Kolte, A., Ahlers, O., Oswald, M., Krauss, V., Roell, D., Sommerfeld, O., Dimοpoulos, G., Tsangaris, I., Antoniadou, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607217 · Cited by 48
Dupuis, C., de Montmollin, É., Buetti, N., Goldgran-Tolédano, D., Reignier, J., Schwebel, C., Domitile, J., Neuville, M., Ursino, M., Siami, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255644 · Cited by 43
“In other clinical settings, studies reported beneficial effects of CS in septic shock [7, 8], and ARDS [9].”
BackgroundWhite, K. C., Costa‐Pinto, R., Blank, S. P., Whebell, S. F., Quick, L., Luke, S., Attokaran, A. G., Garrett, P., Ramanan, M., Tabah, A., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05401-y · Cited by 39
“…beneficial effect of hydrocortisone treatment, a finding that contrasts with results from larger randomized controlled trials such as APPROACHS and ADRENAL, which have suggested its beneficial effects regarding ICU length of stay, duration of shock, and duration of mechanical ventilation [33, 34].”
Self-citationLiang, B., Su, J., Shao, H., Chen, H., & Xie, B. (2023) · Critical Care · doi:10.1186/s13054-023-04392-y · Cited by 43
“Corticosteroids decrease vasopressor requirements in septic shock [47, 48], and the hemodynamic improvement may be due to corticosteroids [34].”
BackgroundCorticosteroid-binding globulin (CBG): spatiotemporal distribution of cortisol in sepsis
Lee, J. H., Meyer, E. J., Nenke, M., Falhammar, H., & Torpy, D. J. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.01.002 · Cited by 43
Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?
Lajoye, Q., Orieux, A., Boyer, A., Prével, R., & Jozwiak, M. (2025) · Critical Care · doi:10.1186/s13054-025-05540-2 · Cited by 41
“…rare (1 patient out of 1,157) or unspecified in the two recent pivotal trials on the effects of corticosteroids in patients with septic shock [150, 151], we believe that the administration of vasopressin and corticosteroids should be considered in combination in patients with refractory septic…”
Butler, E., Møller, M. H., Cook, O., Granholm, A., Penketh, J., Rygård, S. L., Åneman, A., & Perner, A. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05754-3 · Cited by 37
“Four additional studies were included in the meta-analysis (two studies [20, 21] were found during hand-searching and another two [22, 23] following the updated database search on 20th December 2018) resulting in 55 trials being included in total.”
BackgroundSelf-citationBiomarkers and Precision Medicine
Sarma, A. A., Calfee, C. S., & Ware, L. B. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2019.08.012 · Cited by 42
Mentzelopoulos, S. D., Pappa, E., Malachias, S., Vrettou, C. S., Giannopoulos, A., Karlis, G., Adamos, G., Pantazopoulos, I. N., Megalou, A. J., Louvaris, Z., et al. (2022) · Resuscitation Plus · doi:10.1016/j.resplu.2022.100252 · Cited by 40
Kuperminc, E., Heming, N., Carlos, M., & Annane, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093340 · Cited by 48
Кirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Ahn, J. H., Oh, D. K., Huh, J. W., Lim, C., Koh, Y., & Hong, S. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.03.03 · Cited by 36
“Hypertension 23 [31] 12 [34] 11 [28] 0.”
Use of glucocorticoids in the critical care setting: Science and clinical evidence
Chan, E. D., Chan, M. M., Chan, M. M., & Marik, P. E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107428 · Cited by 39
Sepsis in children: federal clinical guideline (draft)
Lekmanov, A. U. (2021) · Russian Journal of Pediatric Surgery Anesthesia and Intensive Care · doi:10.17816/psaic969 · Cited by 44
Cortisol, Stress, and Disease—Bidirectional Associations; Role for Corticosteroid-Binding Globulin?
Lee, J. H., Meyer, E. J., Nenke, M. A., Lightman, S. L., & Torpy, D. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae412 · Cited by 41
Clinical trial design for unmet clinical needs: a spotlight on sepsis
Vincent, J., & Sakr, Y. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1643235 · Cited by 37
Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road Ahead
Leligdowicz, A., Harhay, M. O., & Calfee, C. S. (2022) · NEJM Evidence · doi:10.1056/evidra2200118 · Cited by 41
Pitre, T., Pauley, E., Chaudhuri, D., Saha, R., Rudd, K. E., Villar, J., Berry, L. R., Lorenzi, E., Hills, T. E., Nichol, A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07912-2 · Cited by 36
Self-citationOverexpression of Gilz Protects Mice Against Lethal Septic Peritonitis
Ballegeer, M., Vandewalle, J., Eggermont, M., Isterdael, G. V., Dejager, L., Bus, L. D., Decruyenaere, J. M. A., Vandenbroucke, R. E., & Libert, C. (2018) · Shock · doi:10.1097/shk.0000000000001252 · Cited by 38
“Despite recent results of a successful clinical trial, it still remains unclear which patients will benefit from GC treatment (8, 9).”
BackgroundRisk factors for new-onset atrial fibrillation on the general adult ICU: A systematic review
Bedford, J., Harford, M., Petrinic, T., Young, D., & Watkinson, P. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.06.015 · Cited by 42
Metadata
- Authors
- Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., & Myburgh, J.
- Affiliations
- The University of Sydney (AU)
- From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydney, the Princess Alexandra Hospital (B.V., C.J.) and Royal Brisbane and Women’s Hospital (J.C.), University of Queensland, and the Wesley Hospital (B.V., J.C.), Brisbane, Austin Hospital (R.B.), the...
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 797-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2784412824
- Cited by
- 1,037
- References
- 40
- Citations by year
- 2026: 111 · 2025: 122 · 2024: 90 · 2023: 106 · 2022: 110 · 2021: 121 · 2020: 149 · 2019: 135 · 2018: 91
- FWCI
- 96.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Repository (Kingston University London) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Health and Medical Research Council (1004108, 1124926)
- Health Research Council of New Zealand (12/206)
- National Institute of Health Research, United Kingdom
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- septic shock, cortisol, mortality, mechanical ventilation, shock resolution, blood transfusion, intensive care unit, sepsis treatment, subgroup analysis, mechanical ventilation duration, vasopressor requirement, glycemic control
- MeSH terms
- Aged, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Hydrocortisone, Infusions, Intravenous, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Rate, Fungemia, Bacteremia, Treatment Outcome, Chemotherapy, Adjuvant, Renal Replacement Therapy, APACHE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.